



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 21<sup>st</sup> JULY 2021

#### PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Ms Ana Batista	Specialist Pharmacist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Ms S Holgate (SH)	Pharmacist ELHT

#### IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

#### 2021/082: APOLOGIES:

Dr T McKenzie (TM)	GP East Lancs
Ms F Iqbal	Senior Pharmacist NHS BwD CCG
Dr S Ramtoola (SR)	Consultant Physician, ELHT
Dr N Amir (NA)	Consultant Microbiologist, ELHT

#### 2021/083: DECLARATION OF INTEREST

None declared

#### 2021/084: MINUTES OF JUNE Teams MEETING:

Accepted as accurate.

#### 2021/085: MATTERS ARISING:

**2020/092: Denosumab** – safety requirements have been incorporated into protocol. VG to circulate and re-check issues raised regarding high-risk patients and what should happen at 10 years. To be brought back to September meeting.

**2021/061: Trimbow®** for asthma – agreed to be added to formulary. VG to feedback to Dr Hafeez. Await LSCMMG updated guideline.

**Resolved: Trimbow® for use in asthma patients to be added to formulary.**

**Traffic Light: AMBER**



## **2021/086 NEW PRODUCT REQUEST [UNLICENSED] – SHORT CHAIN FATTY ACID ENEMAS.**

Requested by consultants for use to resolve symptoms of diversion proctitis where patient is not suitable for further surgical intervention. Members agreed that the effectiveness of this product is not clear, and its length of use needs to be included in a clear pathway.

**Action:** The directorate to provide updated information on dosing, length of treatment, costs & expected patient numbers per year for October meeting.

## **2021/087: LSCMMG CONSULTATIONS (FOR August LSCMMG)**

None received

## **2021/088: LSCMMG RECOMMENDATIONS (from June LSCMMG)**

**Axial Spondyloarthritis Pathway:** The pathway has been updated.  
Acknowledged by ELMMB

**Psoriatic Arthritis Recommended Treatment Pathway:** The pathway has been updated.  
Acknowledged by ELMMB

## **2021/089: JOINT COMMITTEE OF CCGs [JCCCG] COMMISSIONING DECISIONS**

None

## **2021/090: FORMULARY UPDATES**

**Tamoxifen** – request for tamoxifen to be included in formulary for use in women who are assessed as moderate to high risk of familial breast cancer.  
Approved by ELMMB.

**Traffic Light: AMBER**

**Tapentadol MR** – currently Grey, awaiting review, for use in palliative care with neuropathic pain. A request has recently been made for issue from hospice team. It was agreed that further clinical evidence is needed from LSCMMG. LR to request the review is added to current LSCMMG workplan.

**Traffic Light: GREY**

**Levothyroxine oral solution** – the MHRA has issued new prescribing advice for patients who experience symptoms on switching between levothyroxine tablet formulations. It is recommended that patients are prescribed a specific product that is well tolerated. The advice suggests using levothyroxine liquid should symptoms of poor control continue. The liquid remains Black traffic Light on formulary. A Hot Topic has been prepared for practices and will be circulated to members for sharing within teams.

**Traffic Light: BLACK**

**Resolved: Formulary will be amended accordingly.**



### **2021/091: LIRAGLUTIDE [SAXENDA®]**

Currently RED traffic light for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity – as per NICE TA664. Awaiting LSCMMG feedback and link to tier 3 services.

**Traffic Light: RED**

### **2021/092: TESTOSTERONE FOR WOMEN**

For use as a supplement for menopausal women with low sexual desire if HRT alone is not effective. Currently under formal review to be included in part of a menopause pathway guideline, which will also include the use of clonidine.

**Traffic Light: GREY**

### **2021/093: ELHT ORAL ANTICOAGULATION GUIDELINES**

Recently updated to incorporate aspects relating to new NICE guidelines reflecting the use of DOACs. It was requested that it was also reviewed as part of the AF Guidelines. Final document to come back to next meeting.

### **2021/094: STEROID EMERGENCY CARD**

Recent NPSA alert regarding the use of the cards to support early recognition and treatment of adrenal crisis in adults >16 years of age – primary care searches have been implemented and identified patients in need of a card. SJ to attend next medicines safety meeting at the Trust and outcomes to be brought to next meeting in September

### **2021/095: NICE RECOMMENDATIONS (from June)**

**Atezolizumab** monotherapy for untreated advanced non-small-cell lung cancer (TA705) is recommended as an option by NICE.

Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

**Ozanimod** for treating relapsing-remitting multiple sclerosis is not recommended as an option by NICE. (TA706)

Not approved

**Traffic Light: BLACK**

**Nivolumab** for previously treated unresectable advanced or recurrent oesophageal cancer (TA707) is recommended as an option by NICE.

Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

**Budesonide orodispersible** tablet for inducing remission of eosinophilic oesophagitis (TA708) is recommended as an option by NICE.

Approved in line with NICE.

CCG Commissioned

**Traffic Light: AMBER**

**Pembrolizumab** for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709) is recommended as an option by NICE.

Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**



**Ravulizumab** for treating atypical haemolytic uraemic syndrome (TA710) is recommended as an option by NICE.

Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

**Guselkumab** for treating active psoriatic arthritis after inadequate response to DMARDs (TA711) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned - Blueteq form required

**Traffic Light: RED**

#### **AOB**

**2021/097:** For information – ELHT purchasing Andexanet alfa in line with NICE TA697 as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the gastrointestinal tract. Usage will be monitored.

#### **STANDING ITEMS**

#### **2021/096: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES –June 2021**

Minutes acknowledged

**DATE OF NEXT MEETING – Wednesday 15<sup>th</sup> September 2021 12.45pm** via ‘Microsoft Teams’



**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 21st JULY 2021**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
2019/131	<b>Treatment of Vitamin B12 Deficiency Draft</b> – pathway to be developed. Awaiting costings to measure B12.	LR/JV	Nov 21
2020/092	<b>Drug Safety Update – Denosumab</b> Directorate pharmacist to discuss with consultants.	AG/VG	Sept 21
2021/061	<b>ELHT Paediatric PPI Guideline:</b> pathway to be updated. Leaflet updated, await final guideline.	VG	Sept 21
2021/086	<b>New Product Request (unlicensed) – Short Chain Fatty Acids</b> – the directorate to provide updated information on dosing, length of treatment, costs & expected patient numbers per year	SH /VG	Oct 21
2021/091	<b>Liraglutide [Saxenda®]</b> Link to Tier 3 weight loss services. To discuss with LSCMMG	VG	Sept 21
2021/093	<b>ELHT Oral Anticoagulant Guidelines</b> - Final document to come back	VG	Sept 21
2021/094	<b>Steroid Emergency Card</b> SJ to attend next medicines safety meeting at the Trust and outcomes to be brought to next meeting in October	VG/SJ	Oct 21